SNYR
Synergy CHC Corp.1.8500
-0.1100-5.61%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q4 '25
Flat Tummy pivot; beverage roadshows ahead.
Q&A revealed Flat Tummy's ongoing decline from GLP1 weight-loss drugs, with management planning a strategic decision soon—details absent from prepared remarks. Beverage RTDs ramped slowly in Q4 due to August funding and inventory build time, but Q1 2026 already topped full-year 2025; upcoming Costco and BJ's roadshows signal acceleration. Core supplements hold steady yet lag competitors' heavy TV ads, underscoring 2026 relaunch urgency. Normalized gross margins should maintain or improve. No new international subsidiaries planned; focus stays on executing Mexico and U.S. initiatives. Flat Tummy hurts now. Investors will eye TV impact and beverage distribution gains.
Key Stats
Market Cap
20.82MP/E (TTM)
6.61Basic EPS (TTM)
0.28Dividend Yield
0%Recent Filings
8-K
License deal terminated ab initio
Synergy CHC Corp. got hit with Gravity Pharma terminating their Brand License Agreement ab initio on February 27, 2026—the deal that fetched $2.9 million for exclusive FOCUSfactor and Flat Tummy Co. rights in UAE and Turkey. Gravity claims it's void from the start. Company pushes ahead with IP registration there. Revenue reversal looms.
10-Q
Q3 FY2025 results
Synergy CHC posted Q3 revenue of $8.0M, up 12% y/y from $7.1M yet flat q/q, with gross margin expanding to 71% from 67% on better product mix. Operating income rose 22% y/y to $1.3M, but net income dipped to $125K from $784K as interest expense doubled to $1.2M from the new $17.5M May 2025 term loan (Term SOFR+8.5%, matures 2029). YTD revenue held steady at $24.3M despite lower product sales, boosted by $2.9M license revenue; diluted EPS matched at $0.27 on 9.2M shares. Cash climbed to $1.1M including $100K restricted, while long-term debt sits at $25.1M post-repayments and $3.9M IPO proceeds; operating cash used $3.2M. Customer concentration persists.
8-K
Q3 revenue up 12.4%
Synergy CHC Corp. reported Q3 revenue of $8.0 million, up 12.4% from $7.1 million, with gross margins expanding 370 basis points to 70.9%. Operating income rose 21.8% to $1.28 million, marking the 11th straight profitable quarter, fueled by retail wins at Kroger and Wakefern. Net income dipped to $125.3 thousand. Debt slashed $3.3 million.
8-K
Board shakeup boosts beverages
Synergy CHC Corp. reshuffled leadership on September 22, 2025: director Scott Woodburn resigned to become Head of Strategic Partnerships, driving FOCUSfactor Energy Drink expansion, while Teresa Thompson joined the Board and its key committees. Thompson, a 39-year Costco veteran in vitamins and supplements, earns $25,000 annual cash plus $25,000 equity. Woodburn targets the booming functional beverages market. Expertise bolsters growth push.
8-K
Synergy closes $4.375M offering
Synergy CHC Corp. closed its public offering on August 27, 2025, selling 1,750,000 shares at $2.50 each for $4.375 million in gross proceeds. Underwritten by Bancroft Capital, the deal includes a 45-day option for 262,500 more shares and warrants for 52,500 shares exercisable after 180 days. Net proceeds will fund working capital and general purposes. Yet dilution looms for shareholders.
BHC
Bausch Health Companies Inc.
6.93+0.02
CAH
Cardinal Health, Inc.
197.89-2.07
COR
Cencora, Inc.
341.72-8.60
COSM
Cosmos Health Inc.
0.50+0.09
HLYK
HealthLynked Corp.
1.67-0.22
HYEX
HEALTHY EXTRACTS INC.
1.99-0.22
PBH
Prestige Consumer Healthcare In
61.60-0.26
SYIN
Synbio International Inc.
0.00-0.00
YCBD
cbdMD, Inc.
1.43+0.23
YJGJ
Yijia Group Corp.
1.61+0.00